These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 27741278)
1. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. Collinson-Pautz MR; Slawin KM; Levitt JM; Spencer DM PLoS One; 2016; 11(10):e0164547. PubMed ID: 27741278 [TBL] [Abstract][Full Text] [Related]
2. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173 [TBL] [Abstract][Full Text] [Related]
3. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Colluru VT; McNeel DG Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128 [TBL] [Abstract][Full Text] [Related]
4. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904 [TBL] [Abstract][Full Text] [Related]
6. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination. Kratky W; Reis e Sousa C; Oxenius A; Spörri R Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17414-9. PubMed ID: 21987815 [TBL] [Abstract][Full Text] [Related]
7. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864 [TBL] [Abstract][Full Text] [Related]
8. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230 [TBL] [Abstract][Full Text] [Related]
9. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442 [TBL] [Abstract][Full Text] [Related]
10. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity. U'Ren L; Kedl R; Dow S Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080 [TBL] [Abstract][Full Text] [Related]
12. Targeting interferon-alpha to dendritic cells enhances a CD8 Graham JP; Authie P; Karolina Palucka A; Zurawski G Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486 [TBL] [Abstract][Full Text] [Related]
13. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. Narayanan P; Lapteva N; Seethammagari M; Levitt JM; Slawin KM; Spencer DM J Clin Invest; 2011 Apr; 121(4):1524-34. PubMed ID: 21383499 [TBL] [Abstract][Full Text] [Related]
14. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
16. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409 [TBL] [Abstract][Full Text] [Related]
17. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency. Wang ST; Chang CC; Yen MC; Tu CF; Chu CL; Peng YT; Chen DY; Lan JL; Lin CC Gene Ther; 2011 Apr; 18(4):372-83. PubMed ID: 21107437 [TBL] [Abstract][Full Text] [Related]
18. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo. Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535 [TBL] [Abstract][Full Text] [Related]
19. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset. Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900 [TBL] [Abstract][Full Text] [Related]
20. In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8 Sales NS; Silva JR; Aps LRMM; Silva MO; Porchia BFMM; Ferreira LCS; Diniz MO Vaccine; 2017 Dec; 35(52):7240-7249. PubMed ID: 29174677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]